Clinical Trials
179 trialsSYRUS
AstraZeneca
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
National Institutes of Health Clinical Center (CC)
CART123
Children's Hospital of Philadelphia
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Memorial Sloan Kettering Cancer Center
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Novartis
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
National Institutes of Health Clinical Center (CC)
Natural History Study of GATA2 Deficiency and Related Disorders
National Institutes of Health Clinical Center (CC)
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
National Institutes of Health Clinical Center (CC)
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
M.D. Anderson Cancer Center
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Dana-Farber Cancer Institute
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center
xDRIVE for Florida-based Cancer Patients
First Ascent Biomedical Inc.
MYELOMONO-3
Gustave Roussy, Cancer Campus, Grand Paris
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Children's Oncology Group
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
HALTAging-1
University of Nebraska
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Pfizer
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Memorial Sloan Kettering Cancer Center
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Medical College of Wisconsin
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc.
LeukemiaCort
University Children's Hospital Basel
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Eastern Cooperative Oncology Group
OHGW-ACP
Azienda USL Reggio Emilia - IRCCS
iCaRe2
University of Nebraska
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Karolinska University Hospital
APEX
Cogent Biosciences, Inc.
Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc.
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
M.D. Anderson Cancer Center
QuANTUM-WILD
Daiichi Sankyo
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
ImmunityBio, Inc.
CD4CAR for CD4+ Leukemia and Lymphoma
Indiana University
PEACE
Massachusetts General Hospital
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Dren Bio
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
Pre-malignant States to Hematologic Malignancies in Firefighters
Wake Forest University Health Sciences
QUATRO-APL
Quetzal Therapeutics
OPAL
AVM Biotechnology Inc
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Children's Hospital of Philadelphia
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
SDSR
Boston Children's Hospital
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Dana-Farber Cancer Institute
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
QUADvance
AvenCell Therapeutics, Inc.
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
Revumenib in Combination With 7+3 + Midostaurin in AML
Dana-Farber Cancer Institute
AUGMENT-101
Syndax Pharmaceuticals
CIML NK Cells With Venetoclax for AML
Dana-Farber Cancer Institute